Open AccessLong term use of bevacizumab in the treatment of triple negative breast cancer with giant tumor in chest wall
Author(s) -
Xinyu Gui,
Huiping Li,
Gonghua Song,
Bin Shao,
Hanfang Jiang
Publication year - 2018
Publication title -
medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.59
H-Index - 148
eISSN - 1536-5964
pISSN - 0025-7974
DOI - 10.1097/md.0000000000013410
Subject(s) - medicine , bevacizumab , triple negative breast cancer , breast cancer , metastasis , lesion , chemotherapy , oncology , radiology , cancer , surgery
Rationale: Triple-negative breast cancer (TNBC) is associated with unfavorable prognosis due to lack of targeted agents. Bevacizumab, an anti-angiogenic monoclonal antibody against vascular endothelial growth factor A, has shown clinical effects in patients with TNBC. Patient concerns: We reported a 49-year-old woman presenting with a giant breast tumor. Diagnoses: Stage IV TNBC with chest wall metastasis. Interventions: The patient underwent long-term use of bevacizumab combined with chemotherapy. Outcomes: The patient was on follow-up for 46 months, a remarkable improvement of the chest wall cutaneous lesion was observed. Lessons: Bevacizumab may provide benefits for TNBC patients with chest wall metastasis.